BTIG Research upgraded shares of Organogenesis (NASDAQ:ORGO – Get Rating) from a neutral rating to a buy rating in a research note released on Tuesday, The Fly reports.
Organogenesis Price Performance
NASDAQ:ORGO opened at $3.44 on Tuesday. The firm has a market capitalization of $451.53 million, a price-to-earnings ratio of 31.28 and a beta of 1.52. Organogenesis has a 52-week low of $1.79 and a 52-week high of $6.52. The stock has a fifty day moving average of $2.23 and a 200 day moving average of $2.50. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.51 and a current ratio of 2.85.
Organogenesis (NASDAQ:ORGO – Get Rating) last posted its quarterly earnings data on Wednesday, March 1st. The company reported $0.06 earnings per share (EPS) for the quarter. The company had revenue of $115.52 million during the quarter. Organogenesis had a return on equity of 8.03% and a net margin of 2.92%.
Insider Activity at Organogenesis
Institutional Investors Weigh In On Organogenesis
Hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its stake in Organogenesis by 886.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 259,177 shares of the company’s stock worth $697,000 after purchasing an additional 232,913 shares during the last quarter. Point72 Hong Kong Ltd lifted its stake in Organogenesis by 210.9% during the third quarter. Point72 Hong Kong Ltd now owns 18,699 shares of the company’s stock worth $61,000 after purchasing an additional 12,684 shares during the last quarter. Royce & Associates LP bought a new stake in Organogenesis during the third quarter worth about $54,000. Tower Research Capital LLC TRC lifted its stake in Organogenesis by 31.2% during the third quarter. Tower Research Capital LLC TRC now owns 83,319 shares of the company’s stock worth $270,000 after purchasing an additional 19,823 shares during the last quarter. Finally, ExodusPoint Capital Management LP lifted its stake in Organogenesis by 1,095.5% during the third quarter. ExodusPoint Capital Management LP now owns 180,455 shares of the company’s stock worth $585,000 after purchasing an additional 165,360 shares during the last quarter. Institutional investors own 47.03% of the company’s stock.
Organogenesis Holdings, Inc is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
- Get a free copy of the StockNews.com research report on Organogenesis (ORGO)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.